• Address: Pent House, Maina Court, Plot 252, Hebert Macaulay Way
    Central Business District Area, Abuja, Nigeria.

  • Call Us: +234 (807) 0986 179
    info@ihvn-irce.org

HIV/AIDS Prevention and Treatment


Strategic Timing of Antiretroviral Treatment (START Study)
PI- Dr Ernest Ekong (IHV-Nigeria as part of the INSIGHT Network (International Network for Strategic Initiatives in Global HIV Trials)
Funder: NIH; Grant Number: U01 AI068641
Duration: 2019-2021
Study Design: Prospective cohort study
Study Population: HIV infected individuals on therapy
Summary: START is an international randomized trial that determined whether starting antiretroviral therapy (ART) early (before CD4 drops to less than 500 cells/mm³), rather than waiting until CD4 drops to less than 350 cells/mm³. The aim is to assess if there are continued differences in clinical outcomes between the two groups.
Study Sites: 222 sites in 33 countries


Trusted Community-Based Ventures Study (BUILDING TRUST Study)
PI: Dr. Man Charurat IHVN Co-Inv: Dr. Nicaise Ndembi
Funder: NIH/ US DOD; Grant Number: CSA2016S-1627
Duration: 2016-2020
Study Design: Longitudinal Observational study
Study Population: Key Pop. (MSM)
Summary: The study aims to investigate strategies for preventing new infections and reducing transmission of HIV among men who have sex with men (MSM) in Nigeria. This study is investigating the use of Treatment as Prevention (TasP) and Pre-exposure Prophylaxis (PreP) preventions. Key findings so far: An association between higher engagement in TasP with disclosure of sexual orientation to health care providers. Also documenting patterns of transmission and trends over time in Nigeria.
Study Sites: 2 Nigerian sites



Adolescent to Adult Patient Centered HIV Transmission (ADAPT Study)

PI: Dr Vicki Tepper; Sub I: Dr. Man Charurat; Sub I: Dr. Ernest Ekong:
Funder: NIH; Grant Number: 1RO1HD089866-01
Duration: 2016 – 2021
Study design: Cluster randomized trial
Study population: 15 to 19-year old ALHIVs in care for at least 1 year
Study Summary: Intervention arms: Peer Transition Advocates (PTAs) vs Education Interventionists (EIs) To measure successful transition and viral suppression in ALHIV transitioned to adult clinic.
Study sites: 6 Nigerian sites



Adolescent Coordinated Transition Study (ACT Study)

PI: Prof Echezona Ezeanolue, Co I: Dr Nadia Sam-Agudu
Funder: NIH; Grant Number: 5R0HD089871-02
Duration: 2016-2020
Study design: Randomized Controlled Trial
Study Population: Adolescents living with HIV
Summary: To evaluate the comparative effectiveness of intervention that combines a transition period with peer-led organized support group compared to usual care that transfers adolescents to adult care without a transitional period. Outcome measures:- Primary- Retention in care at 12 and 24 months post transfer. Secondary- Psychosocial wellbeing and viral suppression at 12 and 24 months post transfer.
Study Sites: 12 Nigerian sites



Dolutegravir and Darunavir Evaluation in adults Failing Therapy (D2EFT study)

PI- Dr Ernest Ekong (Nigeria), INSIGHT Network Trial
Funder: UNSW Australia; Grant Number: UNSW-D2EFT
Duration: 2019-2021
Study Design: A phase IIIB/IV randomized open-label trial
Study Population: HIV infected individuals who have failed first line therapy
Summary: To recruit 200 participants in 2 years. The trial aims to compare:
dolutegravir with pharmaco-enhanced darunavir versus dolutegravir with predetermined nucleosides versus recommended standard of care antiretroviral regimens in patients with HIV infection who have failed recommended first line therapy (the D2EFT study)
Study Sites: 2 Nigerian sites



Human Heredity and Health in Africa (H3Africa) – h3aFRICA Biorepository Initiative

PI- Prof Alash’le Abimiku
Funder: NIH; Grant Number: 5UH3HG007008-06
Duration: 2012-2019
Summary: To upgrade laboratory infrastructure and functions to international standards to support H3Africa investigators in Africa.
The bio-repository supports multiple H3Africa investigators to conduct high quality genomics and translational research in Africa using well processed, preserved and quality controlled and protected human biological samples.
To be accessible to the H3Africa and larger research community to address health issues and diseases affecting the African continent.
Site: IHVN-IHAB



ABOTT/ROCHE Viral Load Evaluation on DBS (ABOTT Study)

PI- Dr. Nicaise Ndembi
Funder: ABBOTT/ROCHE; Grant Number: IIS_3451551
Duration: 2017 – 2019
Study design: Cluster randomized trial
Study population: To recruit 745 patients between the ages 2 to 75 year old ALHIV in care for at least 1 year
Study Summary: Four different sample types were collected (Plasma, Venous DBS, Capillary DBS and Direct blood spotting on DBS). Total sample size of 2980 samples to be assayed. Viral load was tested on both the Roche Taqman 96 and Abbott m2000 platforms.
Study sites: 3 Nigerian states


Maternal, Neonatal and Child Health



Breast Milk Microbiota Influence on Infant Immunity Growth (BEAMING Study)

PI- Prof. Alash’le Abimiku
Funder: NIH; Grant Number: 1U01HD094658-01
Duration: 2018-2022
Study population: Stored samples from HIV-exposed infants in a previous study (Infant study)
Study Summary: This study investigates how breast milk microbiota affects the growth and the ability to respond to childhood vaccinations in HIV exposed but uninfected infants.
Study site: PLASVIREC and Cape Town, SA



Microbiome Affects Risk of Development and Growth in HIV-exposed but Uninfected Infants in Nigeria (MARGIN)

PI: Dr. Man Charurat IHVN Co-Inv: Dr. Nicaise Ndembi
Funder: NIH; Grant Number: 1R01DE025174-10A1
Duration: 2015-2019
Study Design: Case –control study
Study Population: 150 exposed uninfected, 150 unexposed uninfected mother infant pairs
Study Summary: To investigate if the acquisition of an altered gut microbiota from an HIV-infected mother negatively impacts growth and promotes risk of adverse clinical outcomes among HIV exposed but uninfected children.
Study Site: UBTH


Tuberculosis



MTB Infection Rates Among HCWs in HIV Clinics in Nigeria- Tracing Study

PI: Dr Evaezi Okpokoro
Funder: EDCTP; Grant Number: TMA2016CDF1583
Duration: 2019-2021
Study Design: Intervention Study
Study Population: Health care workers who manage TB and HIV patients
Summary: This study aims to measure the risk of MTB infection among HCWs as a surrogate for assessing effectiveness of TB IC control in HIV clinics as well as use this as a platform for strengthening TB IC mechanism and developing policies relevant for protecting this limited but crucial work force. To Train 700 HCWs over a period of 2 years
Study Sites: 14 sites in the FCT and Nassarawa State.


Non-communicable diseases



African Female Breast Cancer Epidemiology (AFBRECANE) Research

PI- Prof Clement Adebamowo
Funder: NIH; Grant number: 5U01HG009784-02
Study Duration: 2017-2021
Study Design: Prospective cohort study
Study Population: Female breast cancer patients
Summary: The project uses data from population based cancer registries (PBCR) to study the epidemiological factors associated with incident breast cancer and molecular subtypes.It also aims to research on genome wide association study (GWAS) of breast cancer in general and of molecular subtypes of breast cancer in indigenous Nigerian women.
Study Sites: 3 Nigerian sites



The African Collaborative Center for Genomics and Microbiome Research (ACCME Study)

PI- Professor Clement Adebamowo
Funder: NIH; Grant number: 3U54HG006947-04S3
Duration: 2014-2019
Study Design: Prospective Cohort Study with nested case control studies
Study Population: 12,000 Nigerian women
Study Summary: Integrative epidemiology research on the associations between high risk (hr) HPV infection, vagina microenvironment, HPV genomics, germline and somatic mutations in the etiology of cervical cancer.
Study Sites: 3 Nigerian sites


Pharmacoepidemiology



Pharmacovigilance Africa (PAVIA Study)

Sub Award PI: Pharm. Avong (Nigerian site)
Funder: EDCTP; Grant Number:CSA2016S-1627
Duration: 2018-2022
Study Design: Implementation Science
Summary: Developing a Pharmacovigilance system in Four African countries
Study Sites: Nigeria, Ethiopia, Swaziland and Tanzania
(Nigeria- UBTH, NAFDAC, IHVN)


Malaria



The Malaria Prevalence Study (MAPS)

PI: Dr. Nankelu Eriobu
Funder: International Society of Blood Transfusion (ISBT)
Duration: 2019-2019
Study Design: Prevalence survey
Summary: Evaluating the prevalence of Malaria Parasitemia among blood donors donating blood to children 0-10 years in Abuja, Nigeria (Malaria positivity identifying the specie of the MP parasite, the parasite count)
Study Sites: National Hospital, UATH